Takeda Completes Acquisition of Shire Earlier Than Expected

By Staff
Tuesday, January 15, 2019 12:24 AM OSAKA, Japan—Takeda Pharmaceutical Company Ltd. (TSE:4502/NYSE:TAK) announced late last week that it has completed its previously announced acquisition of Shire plc. Takeda said that, with the closing of the estimated $62 billion deal, it has become “a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan.” Takeda now will have an expanded geographic footprint and a leading position in Japan and the U.S., and will be in position to bring its innovative medicines to approximately 80 countries and/or regions with dedicated employees worldwide, the announcement noted.

Ocular Therapeutix Added to Nasdaq Biotechnology Index

By Staff
Friday, December 28, 2018 12:18 AM BEDFORD, Mass.—Ocular Therapeutix Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye, has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), according to a recent announcement. Ocular Therapeutix’s addition to the NBI became effective Monday, Dec. 24. Ocular Therapeutix's first product, ReSure Sealant, is FDA-approved to seal corneal incisions following cataract surgery. Ocular Therapeutix is developing innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, according to the company’s recent announcement.

Zeiss Group Reports Record Revenues and Earnings

By Staff
Wednesday, December 19, 2018 12:21 AM STUTTGART, Germany—The Zeiss Group reported a strong performance in fiscal year 2017/18, the period ending Sept. 30, 2018. The company said it achieved record-breaking revenue and earnings. Revenue increased by 9 percent to €5.817 billion (previous year: €5.348 billion). After currency adjustments, revenue rose by 12 percent. Earnings performance helped fully compensate for the unfavorable currency effects. Thus, at €772 million, earnings before interest and taxes (EBIT) were slightly higher than the previous year (€770 million). The EBIT margin was 13 percent. Order intake increased by 7 percent, totaling €6.046 billion.

Multibrands Exercises Option Rights Relating to Safilo Group’s Capital Increase

By Staff
Wednesday, December 5, 2018 12:21 AM PADUA, Italy—Safilo Group S.p.A. said Tuesday afternoon that its major shareholder, Multibrands Italy BV, a subsidiary of HAL Holding NV, exercised its option rights on Monday and paid for subscription of the new shares relating to its existing holding (approximately 41.6 percent) of an ongoing capital increase. The amount involved in the exercise of the option rights totaled approximately €62.4 million, according to the Safilo announcement. Monday, Dec. 3, was the first day of the offering period and first day that Multibrands could exercise its options, under terms approved late last week by Italy’s CONSOB, as VMAIL reported.

EyeSouth Partners Continues Expansion With Georgia Eye Associates Investment

By Staff
Tuesday, November 20, 2018 12:27 AM ATLANTA—EyeSouth Partners, an eyecare-focused physician services organization formed by Shore Capital Partners,  has completed a strategic partnership with Georgia Eye Associates.

National Vision’s Secondary Offering Pricing Set

By Staff
Tuesday, November 20, 2018 12:15 AM DULUTH, Ga.—National Vision Holdings Inc. (NASDAQ: EYE) reported late last week that the public price of its previously announced secondary offering will be $40.50 per share.

National Vision Reports 67th Straight Quarter of Same-Store Sales Growth

By Staff
Wednesday, November 14, 2018 12:24 AM DULUTH, Ga.—National Vision Holdings Inc. (NASDAQ: EYE) reported Tuesday that its sales rose 11.9 percent to $387.4 million in the third quarter, which ended Sept. 29. The increase was driven, in part, by a same-store sales increase of 7 percent (6.8 percent on an adjusted basis), which marked the 67th consecutive quarter of positive comparable-store sales growth for National Vision, according to an announcement from the company. Sales in the year-ago quarter totaled $346.1 million.

New Look Reports Record Results for 3Q 2018

By Staff
Wednesday, November 14, 2018 12:21 AM MONTREAL—Canadian optical retailer New Look Vision Group (TSX: BCI) reported record results for the third quarter ended Sept. 29, 2018. Revenues increased by 32.0 percent over last year to $72.9 million, mainly as a result of New Look’s acquisition of the Iris group in 2017, as well as comparable store sales growth. Comparable store sales orders rose 0.2 percent compared to the third quarter of last year, marking New Look’s 17th consecutive quarter of comparable store sales growth.

Clearside Biomedical Reports Loss for Third Quarter and Provides Pipeline Update

By Staff
Tuesday, November 13, 2018 12:21 AM ALPHARETTA, Ga.—Clearside Biomedical Inc. (NASDAQ: CLSD), a biopharmaceutical company that develops treatments that restore and preserve vision, reported a net loss for the third quarter of $23.9 million. This compared with a net loss of $18.3 million for the third quarter of 2017. The increase in net loss was “primarily attributable to higher R&D expenses in the third quarter of 2018,” the company said in an announcement last week. The company reported no revenue for its third quarter, which ended Sept. 30.

Eye Health America Acquires Updegraff Laser Vision to Expand Southeast Presence

By Staff
Wednesday, November 7, 2018 12:24 AM ATLANTA—Eye Health America (EHA), an eyecare practice management company formed last year, has acquired Tampa Bay, Fla.-based Updegraff Laser Vision.

Bausch Health Reports ‘Organic’ Sales Growth Across All Business Segments

By Staff
Wednesday, November 7, 2018 12:21 AM LAVAL, Quebec—Bausch Health Companies (NYSE/TSX: BHC) reported Tuesday that its revenues totaled $2.14 billion in the third quarter, a decline of 4 percent ($83 million) compared with $2.22 billion in the year-ago period.

Allergan Reports Third Quarter Results Showing ‘Momentum’ in Core Business

By Staff
Wednesday, October 31, 2018 12:24 AM DUBLIN—Allergan plc (NYSE: AGN) reported Tuesday that its third quarter net revenues decreased 3 percent to $3.91 billion compared with the year-ago quarter as the loss of patent exclusivity on some brands weighed on top-line sales. The company also raised its full year sales and income guidance as sales of its “top-promoted products”—including Botox, Vraylar, Juvederm, Loestrin and Alloderm—are expected to drive revenue performance, according to the announcement. Sales of Restasis, a treatment for dry eye, declined 18.8 percent in the third quarter to $298.0 million, although the drop-off in sales during the quarter “were not as severe due to a delay in the launch of cheaper copycats of the dry eye treatment,” according to a Reuters report.

Update: Philadelphia-Based Vantage EyeCare Announces Addition of Three New Divisions

By Staff
Tuesday, October 30, 2018 12:24 AM PHILADELPHIA—Vantage EyeCare LLC, which was formed earlier this year with the intention of becoming the largest, private ophthalmology group in Pennsylvania, New Jersey and Delaware, has added three eyecare companies to its operations, according to an announcement Friday.

Safilo Group Confirms Execution of New €150 Million Financing Agreement

By Staff
Tuesday, October 30, 2018 12:21 AM PADUA, Italy—Safilo Group S.p.A.  confirmed on Monday a comprehensive refinancing plan announced on Sept. 26 this year, as VMAIL previously reported.

Essilor Posts 4.4 Percent Rise in 3Q Revenue

By Staff
Tuesday, October 23, 2018 12:30 AM CHARENTON-LE-PONT, France—EssilorLuxottica (Euronext Paris: EL), Essilor International’s new corporate name since it combined with Luxottica Group S.p.A. (MTA: LUX) on Oct., 1, 2018, posted a 4.4 percent increase in revenue, up 5 percent like-for-like, to €1.8 billion.